tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Relmada Therapeutics Reports Q3 2025 Financial Results
PremiumCompany AnnouncementsRelmada Therapeutics Reports Q3 2025 Financial Results
1M ago
Relmada Therapeutics Reports Q3 2025 Financial Results
Premium
Company Announcements
Relmada Therapeutics Reports Q3 2025 Financial Results
1M ago
Is RLMD a Buy, Before Earnings?
Premium
Pre-Earnings
Is RLMD a Buy, Before Earnings?
1M ago
Relmada Therapeutics appoints Max Kates to clincal advisory board
PremiumThe FlyRelmada Therapeutics appoints Max Kates to clincal advisory board
2M ago
Relmada Therapeutics Updates Corporate Presentation on NDV-01
Premium
Company Announcements
Relmada Therapeutics Updates Corporate Presentation on NDV-01
3M ago
Relmada Therapeutics regains compliance with Nasdaq min bid price requirement
Premium
The Fly
Relmada Therapeutics regains compliance with Nasdaq min bid price requirement
3M ago
Relmada Therapeutics CMO Purchases 55,000 Shares
PremiumCompany AnnouncementsRelmada Therapeutics CMO Purchases 55,000 Shares
4M ago
Relmada Therapeutics’ Earnings Call Highlights Positive Momentum
Premium
Company Announcements
Relmada Therapeutics’ Earnings Call Highlights Positive Momentum
4M ago
Relmada Therapeutics Reports Promising Trial Results
Premium
Company Announcements
Relmada Therapeutics Reports Promising Trial Results
4M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100